Contemporary immunosuppression in renal transplantation

Urologic Clinics of North America

Volumn 28, Issue 4, 2001, Pages 733-750

  Luke, Patrick P W ^a   Jordan, Mark L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 2 (3 DIMETHYLAMINOPROPYL) 8,8 DIPROPYL 2 AZASPIRO[4.5]DECANE; ALEMTUZUMAB; AZATHIOPRINE; BREQUINAR; CALCINEURIN INHIBITOR; CORTICOSTEROID; CORTISONE; CYCLOSPORIN A; CYTOKINE ANTIBODY; EVEROLIMUS; FINGOLIMOD; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; KETOCONAZOLE; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MIZORIBINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PREDNISONE; RAPAMYCIN; TACROLIMUS; TERIFLUNOMIDE; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0035667645     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(01)80029-X     Document Type: Article

References (165)

1. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival
2. Role of the CD28: B7 costimulatory interaction in alloimmune responses
3. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
4. Deoxyspergualin: Clinical trials in renal graft rejection
5. Pooled human IgG modulates cytokine production in lymphocytes and monocytes
6. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients
7. Immunosuppression by glucocorticoids: Inhibition of NF-κβ activity through induction of Iκβ synthesis
8. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients
9. Prevention of rejection with BTI-322 after renal transplantation (results at 9 months)
10. Effect of cortisone on survival of skin homografts in rabbits
11. Incidence and consequences of post-transplantation lymphoproliferative disorders
12. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
13. A randomized, double blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients
14. Beneficial effect of sandoglobulin upon allograft survival in the pediatric renal transplant recipient
15. Renal transplantation in man: A review
16. Cyclosporine A in patients receiving renal allografts from cadaver donors
17. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients
18. A randomized clinical trial of cyclosporine in cadaveric renal transplantation
19. Analyses of the UNOS scientific renal transplant registry at three years: Early events affecting transplant success
20. Immunosuppressive biological agents
21. Renal transplantation in a new immunosuppressive era
22. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection
23. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: A Cooperative Clinical Trials in Transplantation pilot study
24. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients
25. The clinical value of antilymphocyte antibodies
26. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts
27. Current and future application of monoclonal antibodies in clinical imunosuppressive protocols
28. Brequinar sodium
29. Cytokines and transplantation: Th1/Th2 paradigm and the allograft response
30. One month prophylactic use of OKT3 in cadaver kidney transplant recipients
31. Immunosuppressive strategies in transplantation
32. Neurologic complications of FK506
33. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
34. Cyclosporine in cadaveric renal transplantation: One-year follow-up of a multicentre trial
35. Mycophenolate mofetil in renal transplantation: 3-Year results from the placebo-controlled trial
36. The azaspirane SKF 105685 ameliorates renal allograft rejection in rats
37. Population pharmacokinetics of sirolimus in kidney transplant patients
38. An update on new immunosuppressive drugs undergoing preclinical and clinical trials: Potential applications in organ transplantation
39. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporine A
40. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation
41. Gene therapy in transplantation
42. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival
43. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: Its effects on cellular, growth factor, and cytokine response in injured vessels
44. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
45. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation
46. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients
47. Immunosuppressive drugs
48. A randomized, prospective, double-blinded study of cyclosporine vs. OG37-325 in cadaveric renal transplantation - A preliminary report
49. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized study
50. FK506-associated thrombotic thrombocytopenic purpura
51. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
52. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations
53. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients. A meta-analysis
54. Influence of anti-rejection therapy on the timing of cytomegalo-virus disease and other infections in renal transplant recipients
55. OKT3 for the treatment of steroid-resistant acute renal allograft rejection
56. The role of cold ischemia in a provincial organ sharing program in the cyclosporine era
57. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression
58. Tacrolimus rescue therapy for renal allograft rejection-five year experience
59. FK506 'rescue' for resistant rejection of renal allografts under primary cyclosporine immunosuppression
60. Post-transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanisms of action
61. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
62. Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation
63. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
64. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation
65. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients
66. Short course single agent therapy with an LFA3-IgG1 fusion protein prolongs primate cardiac allograft survival
67. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal allograft recipients
68. Regulation of new DNA synthesis in mammalian cells by cyclosporine: Demonstration of transforming growth factor β-dependent mechanism of inhibition of cell growth
69. FK506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK506 in vitro
70. CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates
71. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
72. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
73. A novel mechanism of glucocorticoid-induced immune suppression: The inhibition of T cell-mediated terminal maturation of a murine dendritic cell line
74. A review of FK506: A new immunosuppressant agent for the prevention and rescue of graft rejection
75. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta T cell receptor
76. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation
77. Prevention of kidney and skin allograft rejection in rats by leflunomide, a new immunosuppressive agent
78. CD28 signaling causes a sustained down-regulation of 1 kappa B alpha which can be prevented by the immunosuppressant rapamycin
79. Longterm acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
80. Prevention and reversal of renal allograft rejection by antibody against CD45RB
81. Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation
82. Inhibition of interleukin-2 receptor expression in normal human T cells by cyclosporine
83. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
84. Factors influencing the pharmacokinetics of cyclosporine in man
85. A randomized trial of cyclosporine and prednisone versus cyclosporine, azathioprine and prednisolone in primary cadaveric renal transplantation
86. Immunosuppression in vivo by a soluble form of CTLA4 T cell activation molecule
87. Prevention and treatment of renal allograft rejection: New therapeutic approaches and new insights into established therapies
88. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation
89. The pathophysiology of Sandimmune (cyclosporine) in man and animals
90. Cyclosporine A versus cyclosporine G: A comparative study of survival, hepatotoxicity, nephrotoxicity, and splenic atrophy in BALB/c mice
91. The transforming growth factor-β family
92. ALG treatment of steroid-resistant rejection in patients receiving cyclosporine
93. Sirolimustacrolimus combination immunosuppression
94. FK506 in kidney transplantation: Results of the USA Randomized Comparative Phase III Study
95. Advantages of mizoribine over azathioprine in combination therapy with cyclosporine for renal transplantation
96. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis
97. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury
98. Immunosuppressive effects of the morpholinoethylester mycophenolic acid (RS-61443) in rat and nonhuman primate allografts
99. BTI-322 for acute rejection after renal transplantation
100. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection
101. Randomized trial of basilizimab versus placebo for control of acute rejection in renal allograft recipients
102. Induction of allograft tolerance in rats by an HLA-derived peptide and cyclosporin A
103. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation
104. FK506: Longterm study in kidney transplantation
105. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation
106. Further study of deoxyspergualin prophylaxis in living related renal transplantation
107. FK-506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin
108. 15-Deoxyspergualin "rescue therapy' for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3)
109. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
110. CTLA4Ig plus bone marrow induces long-term allograft survival and donor-specific unresponsiveness in the murine model: Evidence for hematopoeitic chimerism
111. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation
112. Effect of OKT3 in steroid-resistant renal transplant rejection
113. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
114. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients
115. Randomized study with cyclosporine in kidney transplantation: 10 Year follow-up
116. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation
117. Antilymphocyte globulin and monoclonal antibodies
118. Cyclosporine concentration determinations for monitoring and pharmacokinetic studies
119. Deoxyspergualin: Mechanism of action and pharmacokinetics
120. Renal vascular and thrombotic effects of cyclosporine
121. Changes in facial appearance during cyclosporine treatment
122. Microemulsion technology in the reformulation of cyclosporine: The reason behind the pharmacokinetic properties of Neoral
123. Tacrolimus/steroids/mycophenolate mofetil vs. tacrolimus/steroids: Long term impact on rejection
124. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti-ICAM-1 Renal Transplant Study Group
125. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients
126. Mechanisms of T cell recognition of alloantigen: The role of peptides
127. FK506 versus cyclosporin in the prevention of renal allograft rejection: European pilot study six-week results
128. Antimurine antibody formation following OKT3 therapy
129. SDZ RAD, a new rapamycin derivative
130. Drug-induced immunological tolerance
131. Adverse reactions and interactions of cyclosporin
132. FK506 in clinical kidney transplantation
133. The superiority of tacrolimus in renal transplant recipients: The Pitsburgh experience
134. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients
135. Pediatric renal transplantation under tacrolimus-based immunosuppression
136. Reversibility of tacrolimus-induced posttransplant diabetes: An illustrative case and review of the literature
137. Intragraft TGF-β1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy
138. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts
139. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
140. Kidney transplantation under FK506
141. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities
142. Immunosuppression in tissue and organ transplantation
143. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
144. Pharmacokinetics of bredinin in renal transplant patients
145. Overview
146. FK506: Profile of an important new immunosuppressant
147. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte population and imunoglobulin isotype switching in the rat
148. A blinded, long-term randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
149. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
150. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ
151. Mycophenolate mofetil in cadaveric renal transplantation
152. Pharmacokinetics of FK506 following oral administration: A comparison of FK506 and cyclosporine
153. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
154. Treatment of acute cellular rejection with T10B9. 1A-31 or OKT3 in renal allograft recipients
155. The IL-2/IL-2 receptor system: A target for rational immune intervention
156. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide
157. Nonspecific immunosuppression: Azathioprine and steroids
158. Signal transduction by lymphocyte antigen receptors
159. Immunosuppressive effects of leflunomide in a cardiac allograft model
160. New immunosuppressive agents
161. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK506
162. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection
163. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1 (Ala-Ala) in the treatment of acute renal allograft rejection
164. Use of intravenous immunoglobulin in organ transplantation for noninfectious indications